Mayne Pharma has acquired a portfolio of marketed dermatology Foam Assets from GSK for $50.1 million. The assets include U.S. rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam. Mayne Pharma will acquire the approved regulatory filings, trademarks, marketing materials, select product inventory, and will acquire or obtain licenses for related patents.

Fabior Foam, 0.1% is a topical product for the treatment of acne and Sorilux Foam, 0.005% is a topical for mild to moderate plaque psoriasis.

Both Fabior and Sorilux will be marketed through Mayne Pharma’s Specialty Brands Division and existing sales team. Re-launch for both products is expected in FY17. During the intervening period GSK will continue to distribute Fabior and Sorilux under a transition services arrangement.

The non-US dermatology assets will continue to be distributed by GSK in the short term and Mayne Pharma will seek to out-license these products to new partners.